IMM

DirectorsTalk

ImmuPharma $14 million funding in place for Lupuzor

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company has told DIrectorsTalk that registration with the U.S. National Institutes of Health – ClincialTrials.gov website has now gone ‘live’ confirming